Navigation Links
Perrigo Confirms Filing for Generic Version of Men's Rogaine(R) Foam
Date:10/13/2009

ALLEGAN, Mich., Oct. 13 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has filed an Abbreviated New Drug Application for over-the-counter (OTC) Minoxidil topical aerosol foam, 5%, a generic form of Men's Rogaine(®) Foam.

Men's Rogaine(®) (Minoxidil) topical aerosol foam, 5%, is a topical hair re-growth treatment indicated for the re-growth of hair on top of the scalp, and has estimated sales at retail of approximately $52 million annually.

Perrigo filed its ANDA for Minoxidil topical aerosol foam, 5%, containing a paragraph IV certification with the U.S. Food & Drug Administration and notified Johnson & Johnson, the New Drug Application holder for Rogaine(®) Foam, and Stiefel Research Australia Pty. Ltd., the listed patent owner, of its filing. On October 9, 2009, Stiefel Research Australia Pty. Ltd. filed suit alleging patent infringement in the United States District Court for the District of Delaware to prevent Perrigo from proceeding with the commercialization of this product. This action formally initiates the process under the Hatch-Waxman Act.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another example of how our ongoing focus on innovation and consistently bringing new products to market saves consumers money. Over the past 15 years Perrigo products have saved consumers over an estimated $10 billion compared to the national brand."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 29, 2009, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Perrigo Company


'/>"/>
SOURCE Perrigo Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces Approval for Over-the-Counter Childrens Cetirizine Oral Solution
2. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
3. Perrigo Announces FDA Final Approval for Polyethylene Glycol 3350
4. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
5. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
6. Study Confirms That New Protocol Shortens the Time It Takes to Open Blocked Arteries for Heart Attack Patients
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. FDA Confirms Seizure of Eyelash Product Was Not Prompted by Reports of Adverse Effects
9. Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
10. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
11. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Newly published research from ... Institute emphasizes the role a private retailer can play ... The study, published online today in the American ... decision to remove tobacco from all CVS Pharmacy stores ... settings with an even greater impact on those who ...
(Date:2/16/2017)... Summary Provides understanding and access to the allergy partnering ... ... Global Allergy Partnering Terms and Agreements since 2010 report provides understanding ... world,s leading healthcare companies. - Trends in partnering ... by company A-Z, industry sector, stage of development, technology type ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Application, Cancer Type, Technology - Forecast to 2025" report to ... ... at a CAGR of around 28.6% over the next decade to ... of the prominent trends that the market is witnessing include increasing ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has revolutionized ... an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based on ... offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, http://www.fdanews.com/deviceapproval ... asking before selecting an FDA approval pathway? , How should they evaluate ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... 17, 2017 , ... PrideStaff, a national staffing organization, is ... Staffing Industry Analysts' 2017 "Staffing 100 North America" list. , Now in ... to the staffing industry over the last twelve months. Industry insiders and observers ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in and around ... a charity drive to help prevent all forms of domestic violence. , There ...
Breaking Medicine News(10 mins):